Evaluation of Genotoxic Effects of New Molecules with Possible Trypanocidal Activity for Chagas Disease Treatment

Table 7

Micronucleus test with RAW 264.7 macrophages using megazol analogs.

Compound	Dose (μg/mL)	‰ Mi.I.; ± S.D.	% Apoptosis	% Necrosis	% Survival	% Micronucleus ± S.D.
DMSO		6.0 ± 4.2	0.06	0.12	99.8	0.7 ± 0.4
PTAL 05-02	1.0	0.8 ± 0.0*	5.90*	0.16	93.9*	3.5 ± 1.2*
	10	3.0 ± 2.2	7.14*	0.02	92.9*	9.8 ± 6.4*
	100	1.2 ± 0.8*	11.4*	0.06	88.5*	6.6 ± 2.9*
PAMT 09	1.0	2.8 ± 1.6	2.68	0.00	97.3	4.0 ± 4.7
	10	1.2 ± 0.7*	7.32	0.06	92.6	2.7 ± 1.7*
	100	1.2 ± 1.7*	24.7*	0.22	75.0*	0.4 ± 0.2
PTAL 04-09	1.0	3.2 ± 2.4	1.50*	0.00	98.5*	1.2 ± 0.8
	10	1.2 ± 1.4*	2.60*	0.00	97.4*	3.8 ± 1.6*
	100	0.4 ± 1.4*	10*	0.00	90.0*	3.8 ± 1.9*
MNNG		5.2 ± 3.7	0.30	0.00	99.7*	2.8 ± 1.4*

Percentage (%) and per mil (‰) mean and standard deviation (S.D.) of the ratio (samples/negative control) values of at least five experiments.
Negative control was DMSO; positive control was MNNG 0.5 𝜇M; Mi.I.: mitotic index; positive responses marked in bold when samples/negative control ratio ≥1.5. *Representation of a significant response (𝑃≤0.01).